Detalhe da pesquisa
1.
Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.
J Pathol
; 253(1): 41-54, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32901952
2.
Whole-genome characterization of chemoresistant ovarian cancer.
Nature
; 521(7553): 489-94, 2015 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26017449
3.
19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
Gynecol Oncol
; 151(2): 327-336, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30209015
4.
Efficient molecular subtype classification of high-grade serous ovarian cancer.
J Pathol
; 236(3): 272-7, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25810134
5.
Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.
Nature
; 527(7578): 398, 2015 Nov 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26503049
6.
Synthetic lethality between CCNE1 amplification and loss of BRCA1.
Proc Natl Acad Sci U S A
; 110(48): 19489-94, 2013 Nov 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-24218601
7.
Profiling the cancer genome.
Annu Rev Genomics Hum Genet
; 11: 133-59, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20590430
8.
Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes.
J Pathol
; 227(4): 446-55, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22514011
9.
Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.
J Immunother Cancer
; 11(1)2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36720497
10.
The Colorectal cancer RISk Prediction (CRISP) trial: a randomised controlled trial of a decision support tool for risk-stratified colorectal cancer screening.
Br J Gen Pract
; 73(733): e556-e565, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37012077
11.
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.
J Pathol
; 221(1): 49-56, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20229506
12.
Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.
NPJ Breast Cancer
; 7(1): 111, 2021 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-34465787
13.
Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.
Clin Cancer Res
; 15(4): 1417-27, 2009 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19193619
14.
AKT1 gene amplification as a biomarker of treatment response in ovarian cancer: mounting evidence of a therapeutic target.
Gynecol Oncol
; 135(3): 409-10, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25498304
15.
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Clin Cancer Res
; 14(16): 5198-208, 2008 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18698038
16.
Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype.
Clin Cancer Res
; 25(13): 3962-3973, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30967419
17.
Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion.
J Clin Invest
; 129(5): 1940-1945, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30835257
18.
BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition.
JCO Precis Oncol
; 2: 1-14, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35135122
19.
Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.
Clin Cancer Res
; 24(3): 569-580, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29061645
20.
High resolution melting for mutation scanning of TP53 exons 5-8.
BMC Cancer
; 7: 168, 2007 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-17764544